LDLR and atherosclerosis: In addition, in a therapeutic approach, we investigated the impact of hepatic overexpression of soluble uPAR (suPAR) as competitive inhibitor of endogenous membrane bound uPAR in diet-induced atherosclerosis in LDL-receptor-deficient mice.